Alberto Roggi Selected Research

Rifabutin (Ansamycin)

6/2020	Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients.
1/2020	Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alberto Roggi Research Topics

Disease

6	Tuberculosis (Tuberculoses) 01/2021 - 01/2014
2	Hearing Loss (Hearing Impairment) 01/2021 - 06/2020
2	Ototoxicity 01/2021 - 06/2020
1	Coinfection 06/2020
1	Extensively Drug-Resistant Tuberculosis 01/2014

Drug/Important Bio-Agent (IBA)

3	Rifampin (Rifampicin)FDA LinkGeneric 01/2021 - 01/2020
2	Linezolid (Zyvox)FDA Link 01/2021 - 01/2014
2	Lopinavir FDA Link 06/2020 - 01/2020
2	Rifabutin (Ansamycin)FDA Link 06/2020 - 01/2020
2	Ritonavir (Norvir)FDA Link 06/2020 - 01/2020
1	Kanamycin FDA Link 06/2020
1	lopinavir-ritonavir drug combination (Kaletra)FDA Link 01/2020
1	pretomanidIBA 01/2014
1	FluoroquinolonesIBA 01/2014
1	bedaquiline (R207910)IBA 01/2014
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2014
1	OPC-67683IBA 01/2014

Therapy/Procedure

3	Injections 01/2021 - 01/2014